Translational Oncology Research Program

转化肿瘤学研究计划

• 批准号: 10712120
• 负责人: JILL MARIE KOLESAR
• 金额: $ 22.5万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-08 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712120
• 关键词: Address; Antineoplastic Agents; Appalachian Region; Area; Award; Basic Science; Biological Markers; Biological Models; Breast; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Clinic; Clinical; Clinical Oncology; Clinical Trials; Clinical Trials Network; Collaborations; Colorectal Cancer; Communities; Community Outreach; Data; Development; Devices; Diet; Direct Costs; Disparity; EIF4EBP1 gene; Early Therapeutic-Clinical Trials Network; Early identification; Electronics; Enrollment; FASN gene; Fostering; Funding; Future; Genomics; Goals; Gold Compounds; Hydroxychloroquine; Incidence; Individual; Infrastructure; Institution; Interdisciplinary Study; International; Intestinal Hormones; Investigational Drugs; Investigational Therapies; Kentucky; Lead; Leadership; Malignant Neoplasms; Manuscripts; Mediator; Mission; Molecular; Molecular Target; Multi-Institutional Clinical Trial; Mutation; NCI Center for Cancer Research; National Cancer Institute; Natural Products; Nursing Faculty; Obesity; Oncology; Participant; Patient-Focused Outcomes; Patients; Peer Review; Pharmaceutical Preparations; Phase; Phenotype; Population; Prostate; Public Policy; Publications; Publishing; Radiopharmaceuticals; Research; Research Personnel; Research Priority; Resources; Role; Ruthenium Compounds; Science; Strategic Planning; Structure; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Translating; Translations; Tumor Suppressor Proteins; United States National Institutes of Health; Universities; Up-Regulation; Validation; anticancer treatment; cancer care; cancer prevention; cancer therapy; cellular oncology; clinical development; clinical translation; clinical trial enrollment; clinically relevant; college; community engagement; cross disciplinary program; design; drug repurposing; early phase clinical trial; ethnic disparity; genome resource; inhibitor; insight; inter-institutional; intervention program; investigator-initiated trial; member; molecular oncology; mortality; next generation sequencing; novel; novel anticancer drug; novel therapeutic intervention; novel therapeutics; oncology program; phase 1 study; pre-clinical; precision medicine; preclinical development; programs; racial disparity; recruit; repository; translational goal; translational oncology; translational pipeline; translational study; treatment trial; tumor; working group

PROJECT SUMMARY/ABSTRACT The Markey Cancer Center’s (MCC) Translational Oncology (TO) Research Program is scientifically focused on identifying novel targets, discovering new anticancer agents and devices, and leading catchment- relevant clinical trials to decrease cancer burden in Kentucky and the nation. The overarching theme of the TO Program is to use precision medicine to enhance patient outcomes through three Specific Aims: 1) Identify and validate mechanistic targets of cancer, 2) Discover, re-design and develop new anticancer agents and devices, and 3) Develop and lead biomarker directed, catchment-relevant clinical trials. Currently, 33 ongoing translational studies are evaluating molecular targets and mediators of cancer. Since 2018, 38 new drugs, novel combinations and repurposed anticancer agents and devices have been developed, with a focus on identified mutations and phenotypes as informed by COE catchment area data. TO is a cross-disciplinary program with 67 investigators from four colleges and 16 departments producing research awards of approximately $10M in annual direct costs, a 68% increase from 2017, including $1.8M from the NCI and $3.4M from other NIH agencies. Members have published 613 manuscripts (2018 to 2022), of which 148 (24%) are inter-programmatic, 169 (28%) are intra-programmatic, 344 (56%) are inter-institutional, and 13% of which have an impact factor >10. TO members lead 26 new therapeutic interventional investigator-initiated trials (IITs), a 53% increase since the previous funding period (17 IITs, 2013-2017). These IITs have enrolled 870 patients (2018-2022), a 111% increase in IIT accruals (413 patients, 2013-2017), with 52% of participants from Appalachia. In addition, TO investigators enrolled 12,689 individuals to the program’s interventional and non-interventional trials, compared to 8,571 from 2013-2017, a 48% increase. TO Program members are international leaders in target discovery and validation, have national and international collaborations and hold leadership roles in the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network, the Oncology Research Information Exchange Network and Onco-Array Networks, and the MCC-led Global Cancer Consortium. The TO Program fosters continuous collaboration among MCC program members to inform and advance MCC basic science into the clinic. Examples include translating early identification of the biomarker FASN to an ongoing colorectal cancer trial and demonstrating the upregulation of tumor suppressor PAR-4 by hydroxychloroquine in three trials. The TO Program has a cohesive and collaborative team focused on translating MCC scientific discoveries into safe and effective anticancer treatments with a demonstrated depth and breadth of impact in MCC’s catchment area, nationally and internationally.

项目总结/文摘